Male Contraception
2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
YourChoice TherapeuticsCA - San Francisco
2 programs1
1
YCT-529Phase 1/21 trial
YCT-529Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
YourChoice TherapeuticsYCT-529
YourChoice TherapeuticsYCT-529
ContralineADAM System
Clinical Trials (3)
Total enrollment: 129 patients across 3 trials
Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males
Start: Sep 2024Est. completion: Jul 202688 patients
Phase 1/2Recruiting
First in Human Study Evaluating Single Ascending Oral Doses of YCT-529 in Healthy Males
Start: Dec 2023Est. completion: Jun 202416 patients
Phase 1Completed
A First in Human Study, Evaluating the Safety and Efficacy of ADAM™ 1.0
Start: May 2022Est. completion: Mar 202625 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 129 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.